Home / Health / New Hormone Reverses Obesity in Mice
New Hormone Reverses Obesity in Mice
22 Apr
Summary
- A newly identified hormone, FGF21, shows potential to reverse obesity.
- FGF21 targets brain regions similar to GLP-1 drugs but acts differently.
- Mouse study shows FGF21 increases metabolic rate, boosting weight loss.
Scientists have identified a naturally occurring hormone, FGF21, that shows significant promise in reversing obesity. Published in Cell Reports, the study utilized mouse models to demonstrate how FGF21 signals to a specific area of the brain involved in metabolism and appetite regulation. This mechanism is similar to that of popular GLP-1 drugs, though FGF21 operates by increasing metabolic rate rather than solely reducing appetite.
This discovery holds potential for developing new therapies, including treatments for metabolic dysfunction-associated steatohepatitis (MASH). While FGF21 targets the same brain circuitry as GLP-1 analogs, it increases the body's metabolic rate, thereby burning energy and promoting weight loss. Researchers are hopeful this understanding can lead to targeted therapies with fewer side effects.
However, experts note that FGF21 behaves differently in humans. Preclinical mouse studies do not fully replicate human obesity, and obese individuals already have higher FGF21 levels. Early human trials showed modest weight loss compared to GLP-1 treatments, and concerns remain regarding potential side effects like digestive issues and bone loss. Further clinical trials are necessary to confirm efficacy and safety in humans, including bone density monitoring.
